Colon Cancer Symptoms - Erbitux Less Effective For Colon Cancer Patients With Second Gene - Eflux Media
Erbitux Less Effective For Colon Cancer Patients With Second Gene - Eflux Media
Treatment with cetuximab (Erbitux) was less effective for patients with advanced colorectal cancer with a certain gene mutation, a new study found. Scientists already knew that the presence of K-ras mutations explains about 30 to 40 percent of cases
Study Published in New England Journal of Medicine Shows K-ras Gene - MSN MoneyCentral
ImClone Systems Incorporated IMCL and Bristol-Myers Squibb Company BMY today announced the publication of study results showing that metastatic colorectal cancer (mCRC) patients with wild-type or normal K-ras tumors who were treated with
Maui cancer-treatment access to improve - Honolulu Advertiser
WAILUKU, Maui When Robyn Crozier was diagnosed with colon cancer four years ago, she wanted “to fight it with everything I got.” The 44-year-old mother of three said she didn’t hesitate to sign up for a clinical trial of new drug treatment
For cancer patients, personalized treatment offers a new range of - Los Angeles Times
The one thing Kevin Carlberg refused to face after his diagnosis with brain cancer in 2002 was anyone’s estimate for how long he might live. His doctors and his family all knew the number: six to 18 months. “I understand the averages,” says Carlberg
Scientists Find Second Gene That Foils ImClone Drug (Update1) - Bloomberg
Oct. 23 (Bloomberg) — ImClone Systems Inc. and Merck KGaA’s Erbitux, which doesn’t work for advanced colorectal cancer patients with a certain gene mutation, is also futile in people with a second, unrelated aberration, a study found. Patients with